Autres langues G1 Therapeutics, Inc.

Actions

GTHX

US3621LQ1099

Temps réel estimé Cboe BZX Autres places de cotation 15:36:47 26/04/2024			Varia. 5j.	Varia. 1 janv.
3,91 ^USD	+1,30 %		-7,43 %	+26,56 %

28/02	G1 Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
28/02	G1 THERAPEUTICS, INC. : Opinion positive de Wedbush	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024	17/04
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04/04
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04
G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04/03
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/03
G1 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q4 Revenue $14.9M	28/02
G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024	28/02
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights	28/02
G1 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference	27/02
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024	15/02
Top Midday Decliners	13/02
Caution Ahead of Key Inflation Data Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Tuesday	13/02
G1 Therapeutics Gets Nod for Continuing Breast Cancer Study But CEO Notes Lack of 'Positive Interim Analysis'; Shares Drop Premarket	13/02
G1 Therapeutics Gets Continuation Recommendation From Data Monitoring Committee for Phase 3 Breast Cancer Study	13/02
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	12/02
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee	12/02
Life Sciences Ontario Announces Recipients of 2024 LSO Awards	16/01
G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference	08/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues G1 Therapeutics, Inc.

Actions

GTHX

US3621LQ1099

Autres langues

Filtres